CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital

CMR Surgical已完成了一轮超过2亿美元的融资，由现有投资者和新投资者Trinity Capital支持。

The latest funding will fuel the global commercialisation of its Versius Surgical Robotic System, particularly in the U.S. market, and support continued investment in surgical robotics innovation

最新一轮融资将推动其Versius外科手术机器人系统在全球的商业化，尤其是在美国市场，并支持在外科手术机器人创新方面的持续投资。

Versius is the 2nd most adopted soft tissue surgical robot, having been used in over 30,000 surgical procedures worldwide across a wide range of specialties

Versius 是全球第二广泛采用的软组织手术机器人，已在 30,000 多例手术中使用，涵盖多个专业领域。

Cambridge, UK 2 April 2025 07:00 (BST).

英国剑桥，2025年4月2日，07:00（BST）。

CMR Surgical (“CMR” or “the Company”) – the global surgical robotics company – today announced the successful closing of a financing round of over $200 million through a combination of equity and debt capital to support the company’s ambitious growth plans.

CMR Surgical（“CMR”或“公司”）——全球外科手术机器人公司——今天宣布，通过股权和债务资本相结合的方式，成功完成了一轮超过2亿美元的融资，以支持公司雄心勃勃的增长计划。

The fundraising, which was supported by all the Company’s existing major investors, includes a new debt investment from Trinity Capital, reflecting strong investor confidence in CMR’s vision.

此次融资得到了公司所有现有主要投资者的支持，包括来自Trinity Capital的新债务投资，反映出投资者对CMR愿景的强烈信心。

CMR will use the funds to accelerate commercial expansion of the Versius Surgical Robotic System to more hospitals around the world – with a major focus on launching Versius in the United States – and to continue advancing surgical robotics innovation and product development, including the launch of the newly enhanced Versius Plus*..

CMR 将利用这笔资金加快 Versius 外科手术机器人系统在全球更多医院的商业扩展——重点在美国推出 Versius——并继续推进外科手术机器人创新和产品开发，包括推出全新升级的 Versius Plus*。

Versius, the second most utilised soft tissue surgical robot in the world, has been used to complete more than 30,000 surgical cases globally in more than 30 different countries across a wide range of specialities including colorectal, general, gynaecology, thoracic and urology surgeries. The increase in Versius installations has been fuelled by increasing adoption of surgical robotics and is a testament to the versatility of CMR’s system and its strong market differentiation..

Versius 是全球第二大最常使用的软组织手术机器人，已在 30 多个不同国家完成了超过 30,000 例手术案例，涵盖结直肠、普通外科、妇科、胸科和泌尿外科等多个专业领域。Versius 的安装量增加得益于手术机器人应用的日益普及，也证明了 CMR 系统的多功能性及其强大的市场差异化优势。

CMR is also actively expanding its clinical footprint with two ongoing clinical trials: a pioneering paediatrics study, which is the world’s first multicentre prospective trial on the use of Versius in paediatric surgery, and a transoral robotic surgery (TORS) trial, further demonstrating the versatility and capability of Versius in new surgical applications..

CMR还在积极开展两项临床试验，以扩大其临床应用范围：一项是开创性的儿科研究，这是全球首个关于Versius在儿科手术中应用的多中心前瞻性试验；另一项是经口机器人手术（TORS）试验，进一步证明了Versius在新外科应用中的多功能性和能力。

Massimiliano Colella, Chief Executive Officer at CMR Surgical, commented:

CMR Surgical首席执行官马西米利亚诺·科莱拉评论道：

“CMR is a competitive, well-established company with a transformative product providing clear clinical value. We are now at a pivotal stage, poised to capitalise on significant opportunities for market expansion, including in the U.S., while continuing to penetrate deeper into existing markets. I would like to give thanks to our CFO, Andre Nel, and the team for securing this financing to provide the foundation for realising our strategic vision of making robotic assisted surgery accessible to all patients who need it whilst accelerating future product development.

“CMR是一家具有竞争力、根基稳固的公司，拥有能够提供明确临床价值的变革性产品。我们现在正处于一个关键阶段，准备利用重大的市场扩张机会，包括在美国的市场，同时继续深入渗透现有市场。我要感谢我们的首席财务官安德烈·内尔和团队确保了这笔融资，为实现我们的战略愿景奠定了基础，即让所有需要的患者都能获得机器人辅助手术的机会，同时加速未来产品的开发。

I would also like to thank our investors for their continued support and look forward to delivering sustainable growth and life-changing solutions to the global healthcare community.“.

我也要感谢我们的投资者的持续支持，并期待为全球医疗保健界带来可持续的增长和改变生活的解决方案。

Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital, added:

特里尼蒂资本生命科学高级董事总经理罗布·莱克补充道：

“Trinity Capital is excited to partner with CMR Surgical at this important juncture. CMR has established itself as a trailblazer in surgical robotics, with Versius already proving its value to surgeons and patients worldwide. We are confident in CMR’s vision and leadership, and our investment reflects our belief that Versius will continue to drive a new era in minimally invasive surgery.

“Trinity Capital 很高兴能在这一重要时刻与 CMR Surgical 合作。CMR 已经在手术机器人领域确立了先锋地位，Versius 已经证明了其对全球外科医生和患者的巨大价值。我们对 CMR 的愿景和领导力充满信心，我们的投资反映了我们相信 Versius 将继续推动微创手术的新时代。

We look forward to supporting CMR as it continues to scale and transform surgical care on a global level.”.

我们期待继续支持CMR，因为它将继续在全球范围内扩展和变革外科护理。”

Dan Moore, Non-Executive Chairman at CMR Surgical, added:

CMR Surgical的非执行主席丹·摩尔补充道：

“The recent funding is a strong vote of confidence in the future of surgical robotics and in CMR as a leader within this space. This investment is a significant endorsement of Max and his leadership team and provides them with the resources needed to execute on their strategic plan. We are pleased to have the continued support of our investors as we embark on this next phase of growth.”.

“近期的资金注入，是对手术机器人未来以及CMR作为该领域领导者的强烈信任投票。这项投资是对Max及其领导团队的重大认可，并为他们提供了执行战略计划所需的资源。我们很高兴在进入下一阶段增长时继续获得投资者的支持。”

UK Science Minister and Oxford Cambridge Corridor Champion, Lord Vallance said:

英国科学部长、牛津剑桥走廊倡导者瓦兰斯勋爵表示：

“This successful funding round of more than $200M is a clear vote of confidence in the company, the potential of surgical robotics, and in the UK’s life science ecosystem, which continues to produce innovative companies at an impressive rate.

“这笔超过2亿美元的成功融资显然表明了对公司、对手术机器人潜力以及对英国生命科学生态系统的信任，英国生命科学生态系统继续以惊人速度产出创新公司。

“We will continue to back world-class innovation and companies like CMR Surgical as they realise their global ambitions and support the creation of high-quality jobs in the UK.”

“我们将继续支持世界级的创新和像CMR Surgical这样的公司，帮助他们实现全球抱负，并支持在英国创造高质量的就业机会。”

Armentum Partners acted as CMR’s financial advisor on the debt financing.

阿门特姆合伙公司担任了CMR的债务融资财务顾问。

— ENDS —

—— 结束 ——

Media Contacts:

媒体联系人：

For more information, please contact:

更多信息，请联系：

ICR Healthcare

ICR医疗保健

T

T

+44(0) 203 7095700

+44(0) 203 7095700

E

E

cmrsurgical@icrhealthcare.com

cmrsurgical@icrhealthcare.com

Press Office, CMR Surgical

新闻办公室，CMR外科

T

T

+44(0) 1223 755801

+44(0) 1223 755801

E

E

pressoffice@cmrsurgical.com

pressoffice@cmrsurgical.com

Notes to editors:

编辑须知：

The Versius Surgical System is a robotically assisted surgical device that is intended to assist in the precise and accurate control of Versius Surgical endoscopic instruments including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, forceps/pick-ups, needle holders, electrosurgery, and accessories for endoscopic manipulation of tissue, including grasping, cutting, blunt and sharp dissection, approximation, ligation, electrosurgery and suturing.

Versius外科系统是一种机器人辅助手术设备，旨在精确和准确地控制Versius外科内窥镜仪器，包括硬性内窥镜、钝性和锐性内窥镜解剖器、剪刀、镊子/拾取器、持针器、电外科设备以及用于组织内窥镜操作的配件，包括抓取、切割、钝性和锐性解剖、接近、结扎、电外科和缝合。

In the United States, the Versius Surgical System is indicated for adult patients 22 years of age and older, eligible for soft tissue minimal access surgery, for cholecystectomy..

在美国，Versius外科手术系统适用于22岁及以上的成年患者，可进行软组织微创手术，用于胆囊切除术。

*Versius Plus is CE and UKCA marked. Please check availability of the product in your country with your local sales representative or your local customer service. The Versius Plus Instructions for Use, including the approved indications, contraindications and warnings can be found in the product labelling supplied with each Versius System.

*Versius Plus 已获得 CE 和 UKCA 认证。请与您当地的销售代表或客户服务确认您所在国家的产品可用性。Versius Plus 的使用说明书，包括已批准的适应症、禁忌症和警告，可在每个 Versius 系统随附的产品标签中找到。

Versius Plus is not available for sale in the United States..

Versius Plus 在美国不可销售。

The Versius Surgical Robotic System

Versius外科手术机器人系统

Versius resets expectations of robotic surgery. Versius fits into virtually any operating room set-up and integrates seamlessly into existing workflows, increasing the likelihood of robotic minimal access surgery (MAS). The small, portable and modular design of Versius allows the surgeon to only use the number of arms needed for a given procedure..

Versius重新定义了机器人手术的期望。Versius几乎可以适应任何手术室的设置，并无缝集成到现有的工作流程中，增加了机器人微创手术（MAS）的可能性。Versius的小巧、便携和模块化设计使外科医生能够根据特定手术的需要仅使用所需数量的机械臂。

Biomimicking the human arm, Versius gives surgeons the choice of optimised port placement alongside the dexterity and accuracy of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the open surgeon console has the potential to reduce stress and fatigue and allows for clear communication with the surgical team.

通过仿生人类手臂，Versius为外科医生提供了优化的端口放置选择，同时具备小型全腕式器械的灵巧性和精确性。凭借3D高清视野、易于掌握的器械控制以及符合人体工程学的工作姿势选择，开放式的外科医生控制台有助于减轻压力和疲劳，并能够与手术团队进行清晰的沟通。

By thinking laparoscopically and operating robotically with Versius, patients, surgeons and healthcare professionals can all benefit from the value that robotic MAS brings. .

通过使用Versius进行腹腔镜思维和机器人操作，患者、外科医生和医疗专业人员都能从机器人MAS带来的价值中受益。

But it’s more than just a robot. Versius captures meaningful data with its wider digital ecosystem to support a surgeon’s continuous learning. Through the Versius Connect app, Versius Trainer and CMR clinical registry, Versius unleashes a wealth of insights to ultimately improve surgical care.

但 Versius 不仅仅是一个机器人。它通过更广泛的数字生态系统捕获有意义的数据，以支持外科医生的持续学习。通过 Versius Connect 应用程序、Versius Trainer 和 CMR 临床数据库，Versius 释放出丰富的见解，最终提升手术护理水平。

About CMR Surgical Limited

关于CMR外科有限公司

CMR Surgical (CMR) is a global medical devices company dedicated to transforming surgery with Versius, a next-generation surgical robot.

CMR Surgical (CMR) 是一家全球医疗器械公司，致力于通过下一代手术机器人 Versius 实现手术的变革。

Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams and hospital partners, to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius, we are on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care..

总部位于英国剑桥的CMR致力于与外科医生、手术团队和医院合作伙伴共同努力，提供一种优化的工具，使机器人微创手术普及化且负担得起。通过Versius，我们正在通过实用的创新技术和数据改进外科护理，重新定义外科机器人市场。

Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

成立于2014年的CMR Surgical是一家由国际股东支持的私人有限公司。